There will be two groups of patients after drawing lots using a process called randomization. The probability is one in two of being in the group participating in the training program, the other group following the standard treatment.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Woman ≥ 18 years old
Stage I to III breast cancer
Patient currently planning (neo)adjuvant treatment combining anthracycline-cyclophosphamide and weekly paclitaxel (± trastuzumab)
Affiliation to a social security system
Able to speak, read and understand French
You may not be if
No prior chemotherapy treatment
Any known cardiac or vascular pathology
Contraindications to physical fitness assessment
Protected adult
Psychiatric, musculoskeletal or neurological problems
Pregnant or breastfeeding woman (NB: this population is already subject to a contraindication to (neo)adjuvant treatment. For women of childbearing age, a betaHCG dosage is already carried out systematically before the start of chemotherapy and information on the need for contraception throughout the chemotherapy period is provided before the start of treatment. As part of this study, only the presence of this test with a negative result at the start of chemotherapy will be checked. inclusion, if available).
Clareo Health | Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study
